StockData

Mannatech vs Niagen Bioscience

MTEX and NAGE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How MTEX and NAGE compare

Niagen Bioscience is the larger company, worth 22 times as much as Mannatech ($159M against $7.3M).

Niagen Bioscience grew revenue faster over the last twelve months (−1.9% versus −5.0% for Mannatech).

Niagen Bioscience keeps more of each dollar of sales as profit, with a net margin of 8.4% compared with −6.9% at Mannatech.

Niagen Bioscience scores higher on the StockData Score (14 against 8 for Mannatech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricMTEXNAGE
Size and price
Market cap$7.3M$159M
Share price$3.76$2.01
Change, 1 year−60.5%−71.2%
Change, 5 years−90.2%−59.1%
Beta (5Y)0.591.08
Employees387117
StockData Score
Total score814 (better)
Valuation score23 (better)
Growth score11
Performance score14 (better)
Health score46 (better)
Dividend score00
Valuation
P/E–16.8×
P/S0.1× (better)1.3×
P/B–1.9×
EV/EBITDA1.1× (better)18.8×
P/FCF4.5×–
FCF yield22.0%–
Fair value–$2.30
Margin of safety–12.6%
Growth
Revenue growth (TTM)−5.0%−1.9% (better)
Revenue growth, 5Y average−6.5%16.9% (better)
Net income growth (TTM)–−49.9%
EPS growth (TTM)–−50.0%
Profitability
Gross margin76.1% (better)63.9%
Operating margin2.5%3.9% (better)
Net margin−6.9%8.4% (better)
FCF margin1.5%–
Return on equity−406%13.3% (better)
Return on invested capital–44.3%
Financial health
Debt / equity–0.00
Net debt / EBITDA−0.89–
Interest coverage5.9×–
Current ratio1.155.93 (better)
Altman Z-score3.863.87 (better)
Piotroski F-score27 (better)
Dividends and buybacks
Buyback yield–3.4%
Shareholder yield0.00%3.4% (better)
Ownership
Held by institutions7.9%40.4%
Held by insiders–5.1%
Insider net buying, 12 months$62.2K (better)$0
Short interest, % of float–5.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.